Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Guardant Health Inc
(NQ:
GH
)
28.38
+0.43 (+1.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Guardant Health Inc
< Previous
1
2
3
4
5
6
Next >
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
June 18, 2021
From
Guardant Health
Via
Business Wire
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
June 18, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
June 08, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
June 04, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
May 28, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
May 28, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
May 20, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
May 19, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports First Quarter 2021 Financial Results
May 06, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
May 03, 2021
From
Guardant Health, Inc.
Via
Business Wire
Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
April 30, 2021
From
Guardant Health
Via
Business Wire
Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference
April 29, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
April 27, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report First Quarter Financial Results on May 6, 2021
April 12, 2021
From
Guardant Health, Inc.
Via
Business Wire
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
April 10, 2021
From
Guardant Health, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.